PROCLAMATION 6982—APR. 1, 1997 111 STAT. 2871 as National Child Abuse Prevention Month. I call upon all Americans to observe this month by demonstrating our respect and gratitude for those who devotedly and unselfishly work to keep children safe, by learning how we can help keep children from harm's way, and by tak ing responsible actions to protect our precious children. IN WITNESS WHEREOF, I have hereunto set my hand this first day of April, in the year of our Lord nineteen hundred and ninety-seven, and of the Independence of the United States of America the two hun dred and twenty-first. WILLIAM J. CLINTON
Proclamation 6982 of April 1, 1997 To Implement an Agreement To Eliminate Tariffs on Certain Pharmaceuticals and Chemical Intermediates
By the President of the United States of America A Proclamation 1. On December 13, 1996, members of the World Trade Organization (WTO), including the United States and 16 other major trading coun tries, announced in the WTO Singapore Ministerial Declaration an agreement to eliminate tariffs on certain pharmaceuticals and chemical intermediates that were the subject of reciprocal duty elimination nego tiations during the Uruguay Round of multilateral trade negotiations ("Uruguay Round"). In addition, it was agreed that the agreement on pharmaceutical products reached at the conclusion of the Uruguay Round and consequently Schedule XX—United States of America, an nexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (1994) ("Schedule XX") erroneously included 25 products. 2. (a) Section 111(b) of the Uruguay Round Agreements Act (URAA) (19 U.S.C. 3521(b)) authorizes the President to proclaim the modifica tion of any duty or staged rate reduction of any duty set forth in Schedule XX for products that were the subject of reciprocal duty elimination negotiations during the Uruguay Round if the United States agrees to such action in a multilateral negotiation under the aus pices of the WTO and after compliance with the consultation and lay over requirements of section 115 of the URAA (19 U.S.C. 3524). Sec tion 111(b) also authorizes the President to proclaim such modifica tions as are necessary to correct technical errors in Schedule XX or to make other rectifications to the Schedule. (b) Section 111(a) of the URAA (19 U.S.C. 3521(a)) authorizes the President to proclaim such additional duties as the President deter mines to be necessary or appropriate to carry out Schedule XX. 3. Section 604 of the Trade Act of 1974 (1974 Act), as amended (19 U.S.C. 2483), authorizes the President to embody in the Harmonized Tariff Schedule of the United States (HTS) the substance of the rel evant provisions of that Act, and of other acts affecting import treat ment, and actions thereunder, including the removal, modification, continuance, or imposition of any rate of duty or other import restric tion. Ill STAT. 2872 PROCLAMATION 6982—APR. 1, 1997
4. (a) Pursuant to section 111(b) of the URAA, I have determined that modifications to Schedule XX are necessary and that Schedule XX should be modified accordingly. In addition, I have determined to modify the HTS to implement the multilateral agreement on pharma ceuticals negotiated under the auspices of the WTO. (b) Pursuant to section 111(a) of the URAA, I have determined that it is necessary or appropriate to modify the HTS to increase tariffs on products that w^ere included erroneously in the pharmaceuticals agree ment reached at the end of the Uruguay Round. (c) On January 29, 1997, pursuant to section 115 of the URAA, the United States Trade Representative (USTR) submitted a report to the Committee on Ways and Means of the House of Representatives and the Committee on Finance of the Senate ("the Committees") that set forth the proposed tariff eliminations and corrections in existing tariff treatment, together with the advice received from the appropriate pri vate sector advisory committee and the U.S. International Trade Com mission regarding such actions. During the 60-day period thereafter, the USTR consulted with the Committees on the proposed tariff elimi nations and corrections. NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting under the authority vested in me by the Con stitution and the laws of the United States, including but not limited to sections 111(a) and (b) of the URAA and section 604 of the 1974 Act, do hereby proclaim that: (1) In order to implement the multilateral agreement negotiated under the auspices of the WTO to eliminate tariffs on certain pharma ceutical products and chemical intermediates, and to correct errors, Schedule XX and the pharmaceutical appendix to the HTS are modi- J5ed as set forth in the Annex to this proclamation. (2) The modifications to the HTS set forth in this proclamation shall be effective as provided in the Annex to this proclamation. (3) Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are su perseded to the extent of such inconsistency. IN WITNESS WHEREOF, I have hereunto set my hand this first day of April, in the year of our Lord nineteen hundred and ninety-seven, and of the Independence of the United States of America the two hun dred and twenty-first.
WILLIAM J. CLINTON PROCLAMATION 6982—APR. 1, 1997 111 STAT. 2873
Modifications Co the Harmonized Tariff Schedule of the United States ("HTS")
Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after April 1. 1997.
Section A. For subheading 2833.29.50, the Rates of Duty 1 Special subcolumn Is modified by Inserting, In alphabetical order, the symbol *K," In the parentheses following the "Free" rate of duty in such subcolumn.
Section B. The Fharouiceutlcal Appendix ('the Appendix') to the Harmonized Tariff Schedule of the United States ("HTS") Is modified as provided In this section.
(1). Table 1 of the Appendix Is modified by--
(a). changing the CAS number for the following product:
Pfpduct; H^w ^^^M^>gr Old Number
CICLESONIDE 1A184S-82-1 126544-47-6
(b). deleting the following products and their CAS numbers:
Product CAS Nuitxr Product CAS NuBbT
BENZYL ALCOHOL 100-S1-6 NORFLURANE 811-97-2 CALCIkM CARIINIDE 1S6-62-7 PEGOTERATE 25038-59-9 CARIOMEt W182-S7-9 PIMAGEDINE 79-17-4 CARMELLOSE 9000-11-7 POLICAPRAM 2S038-54-4 CHOLINE CHLORIDE 67-48-1 POLITEF 9002-84-0 DIHETICONE 9006-6S-9 PYROXYLIN 90O4-70-0 GLUTAMIC ACID S6-86-0 THIODl GLYCOL 111-48-8 GLYCINE S6-40-6 THREONINE 72-19-5 HYMONELLOSE 9004-6S-3 TRICHLOROETNYLENE 7901-6 LINDANE 58-89-9 TRYPTOPHAN 73-22-5 LYSINE 56-87-1 TYLOMPOL 25301-02-4 NACROGOL 25322-68-3 ZINC ACETATE, BASIC 82279-57-0 MACROCOL ESTER (c). deleting the chemical lume in column A and inserting the chemical name In column B In lieu thereof:
CglMIBTl A gplVWTl.B
ADITOPRIME ADITOPRIM BROMOCYCLEN BROMOCICLEN CARBAZOCHROME SODIUM SULPHONATE CARBAZOCHROME SODIUM SULFONATE CORTICOTROPIN-ZINC HYDROXIDE CORTICOTROPIN ZINC HYDROXIDE ETAMIPHYLLIN ETAMIPHYLLINE FLOCALCITRIOL FALECALCITRIOL FOMEPIZOL FOMEPIZOLE FROFENEM FAROPEKEM GLIPENTIDE GLISENTIDE ISEPAMICINE ISEPAMICIN POLYVIDONE POVIDONE SABMOXILLIN SARMOXICIIXIN
(d). adding the following new INNs, in alphabetical order, along with their CAS nuaberv:
Product Product CASfnafcer
AfCIXIMA* 143653-53-6 APTIGANEL 137159-92-3 AIITESARTAN 137882-98-5 ARTEFLENE 123407-36-3 ACITAZANKAST 114607-46-4 ATEXAKIN ALFA 143631-61-2 AOATANSERIN 127266-56-2 ATKE PRONE 153420-96-3 AOEFOVIR 106941-25-7 ATORVASTATIN 134523-00-5 ASELHIDRCL 1675-66-7 AZALANSTAT 143393-27-5 AFELIMHAB 156227-98-4 AZINIIIDE 149908-53-2 AFCVIKSEN 151356-08-0 MLAZIPONE 137109-71-8 AGLEPRl STONE I2U78-60-0 •ALOFLOXACIN 127294-70-6 ALNACOOMTE CASIFUNGIN 127785-64-2 ALNESPIRONE 138298-79-0 BATIHASTAT 130370-60-4 ALNIOITAN 1S2317-B9-0 lERUPIPAN 150490-SS-O ANAXIMU U30fO-92-0 mVASTATIM 132017-01-7 ANASTROZOU 120511-73-1 KSIPIRDINE 119257-34-0 ANTITHROMBIN III, HUMAN 9000-94-6 KTASIZOFIRAS 39464-87-4 APAXIFYLLINE 151581-23-6 • ICALUTANIOE 90357-06-5 Ill STAT. 2874 PROCLAMATION 6982—APR. 1, 1997
Annex (continued) -2-
Section B. (con.).
(1). (con.)-- (d). (con.):
Product Product CAj mwbtr
•ISMFIDE 1UM9-63-8 IPIDACRINE 62732-44-9 •IVALIRUDIII 12827Q-60-0 IRALUKAST 151581-24-7 U7536-97-8 IRBESARTAN 138402-11-6 CANPESARTAN 13W«1-59-7 ITANELINE 121750-57-0 CANOOCURONIUH ICOIDE M278-8S-2 UFLUNINUS 147076-36-6 CAPECITAIINC 1S4361-S0-9 LAFUTIDINE 118288-08-7 CANOMAI 151763-M-3 LANIFIiAM 14U12-49-7 CARTASTEINC U9079-S1-6 LANPERISONE 116287-14-0 CEFLUPRENAM 1168S3-2S-9 LANPROSTON 105674-77-9 CEFOSELIS 122841-10-5 LAURCETIUN IRONIDE 1794-75-8 CERTOPARIN SODIUM LEDISNASC 149394-67-2 ClOOfOVU 1138S2-37-2 LENAPENEN 149951-16-6 CtLMOSTIN 148637-0S-2 LENERCEPT 156679-34-4 CINALUKAST 128S12-S1-6 LEPIRUDIN 138068-37-8 CtPAMFYLLINE 132210-43-6 LETROZOLE 112809-51-5 CISATMCURIUH BESIUTE 96946-42-8 LEVORNELOXIFENE 78994-23-7 COLESTILAN 9S522-4S-S LEVOSENOTIADIL 116476-16-5 OKMOGLICATE LISETK 110816-79-0 LEXACALCITOL 131875-08-6 OraSPOVIOONE 9003-39-8 LEXIPAFANT 139133-26-9 DACLIXIMAI 1S2923-S6-3 LIREOUINIL 143943-73-1 DAPAIUTAN 6S82-31-6 LISOFYLLINC 100324-81-0 DAIIFENACIN 133099-04-4 LOKICAVIR 127759-89-1 DAHSIDCHINE 137300-42-6 LOVIRIDE 147362-57-0 DELAVimiNE 136817-59-9 LUBELUZOLE 144665-07-6 OELEflUAMINE 119905-05-4 LUTROPIN ALFA 152923-57-4 DENOTIVI* 51287-57-1 NANGAFCOIPIR 155319-91-8 DESimJDtN 120993-53-5 HAPINASTINE 140945-32-0 DETUHOHAI 145832-33-3 MAZAPERTINE 134208-17-6 OEXECAOOTRIl 112573-72-5 NIBEFRAOtl DEXKETOPROFEN 22161-81-5 116644-53-2 DEXPENEDOLAC 114030-U-3 NINOLTEPARIN SODIUM DINAOECTIN 156131-91-8 HIPITROSAN 136122-46-8 DCNITRCSAN 112966-96-8 MIRISETRON 135905-89-4 DORNASE ALFA 143831-71-4 MOeENAKIN 124146-64-1 EBALZOTAN 149494-37-1 NOFAROTENE 125533-88-2 EFEGATRAN 105806-65-3 MONTELUKAST 158966-92-8 EFLETIRIZINE 150756-35-7 MONTEPLASE 156616-Z3-8 ELISARTAN 158682-68-9 NORKTOCOC ALFA ELOPIPRAZOLE 115464-77-2 NUPLESTIN 148641-02-5 EMIOEITIOE 62568-57-4 MURaM0NAS-C03 END NONAS 142864-19-5 NAC0L0HA8 TAFENATOX 150631-27-9 EPOETIN EPSILON 154725-65-2 NADR0(>ARIN CALCIUN EPOETIN ONEGA 148363-16-0 NAPITANE 148152-63-0 EPRINONECTIN 123997-26-2 NAPSACATRAN 154397-77-0 EPROSARTAN 133040-01-4 NATEPLASE 159445-63-3 EPTACOG AlFA (ACTIVATED) 102786-52-7 NENORUBICIN 108852-90-0 ERMiLOZOLE NETIVUDINE 84558-93-0 ERSENTILIOE 125279-79-0 NICANARTINE 150443-71-3 EXANORELIN 140703-51-1 NICOTREDOLE 29876-14-0 FENLEUTON 141579-54-6 NUPAFANT 139133-27-0 FIIRIN, lOVINE KINAPLOM 96604-21-6 FIIRIN, NUNAN OCTOCOC AlFA 139076-62-3 FOOIPIR 118248-91-2 OOULIMCHAB 159445-64-4 FOILITROPIH ALFA 9002-68-0 OLOPATAOINE 113806-05-6 FOZIVUOINE TIDOXIL 141790-23-0 OLPAORONIC ACID 63132-39-8 FRACAFIMN 148396-36-5 OLPRINONE 106730-54-5 FULADECTIN OKTAZOLAST 147432-77-7 GAOOVERSETAMIDE 131069-91-5 ORIENTIPARCIN 159445-62-2 GAOOXETIC ACID 135326-11-3 OXECLOSPORIN 135548-15-1 GALOANSETRCN 116684-92-5 PAHICOCREL 101001-34-7 CECLOSPORIN 74436-00-3 PANAMESINE 139225-22-2 6LENVASTATIN 122254-45-9 PARNAPARIN $00IUN GORALATIDE 120081-14-3 PAZINACLONE 103255-66-9 IBANORONIC ACID 114084-78-5 PAZUFLOXACIN 127045-41-4 ICONETASONE ENHITATE 103466-73-5 PEGORGOTEIN 155773-57-2 IDRANANTONE 20098-14-0 PENTOSAN POLYSULFATE SOOIUN IFETRORAN 143443-90-7 PEROSPIRONE 150915-41-6 IGANIDIPINE 119687-33-1 PI CLAN I LAST 144035-83-6 IlEPCINIDE 82857-82-7 PINILPROST 139403-31-9 ILONASTAT 142880-36-2 PLUSONERMIN ILONIOAP 135202-79-8 POSILUKAST 107023-41-6 IMIOAPRILAT 89371-U-8 POIIXETONIUM CHLORIDE 31512-74-0 INICLUCERASE 154248-97-2 POLYSORBATE 1 9017-37-2 IMITROOAST 114686-12-3 POLYSORBATE 8 9009-51-2 INCAORONIC ACID 124351-85-5 POLYSORBATE 20 9005-64-5 INOGATRAN 15541S-C8-0 POLYSORBATE 21 9005-64-5 INOLINONAS 152981-31-2 POLYSORBATE 40 9005-66-7 INSULIN LISPRO 133107-64-9 POLYSORBATE 60 9005-67-8 INTERFERON ALFA 9008-11-1 POLYSORBATE 61 9005-67-8 INTERFERON BETA 9008-11-1 P0LTSCR8ATE 65 9005-71-4 INTERFERON CANW 9008-11-1 POLYSORBATE 80 90C5-6S-6 lOLOPRIDE (123 1) 113716-48-6 POLYSORBATE 81 9005-65-6 IPENOXAZONE 104454-71-9 POLYSORBATE 85 9005-70-3 PROCLAMATION 6982—APR. 1, 1997 111 STAT. 2875
Annex (continued) -3-
Section B. (con.).
(1). (con.)-- (d). (con.):
Product CAS Miater Product CAS Kjriier
POLYtORMTE 120 15432&2-61-S TAGORIZINE 118420-47-6 MNKMTAN 1U702-17-0 TALSACLIDINE 147025-53-4 PRENAFLOKACIII USWS-6S-7 TAMliAROTENE 94497-51-5 PRIIIXINM 1*7191-91-1 TASOSARTAN 145733-36-4 PMVAGEIWMIUH TAZAROTENE 118292-40-3 PRmiFLaXACIN 123U7-62-1 TAZOFELONE 136433-51-7 OUIFLAPOH 1366M-42-3 TECHNETIUM (99M TO FURIFOSMIN 142481-95-6 RACECADOTRIL 81110-73-S TELINAVIR 143224-34-4 RAMATIOBAN 11«M9-85-S TELHISARTAN 1U701-48-4 RAMOSETRON 132036-W-S TEVERELIX 144743-92-0 RASAGILINE 136236-S1-6 TNTMALFASIN 62304-98'-7 REGAVItUMW 1S3101-26-9 TINZAPARIN SCOIUM REPAGERMWIUH TIROFIRAN 144494-65-5 REVIPARIH SODIUM TOBORINONE 143343-83-3 RICASETRON 117086-68-7 TOUFENTRINE 139308-65-9 RIPISMTAN 148S04-S1-2 TRADECAHIDE 132787-19-0 ROCEPAFANT 132«18-36-1 TROVAFLOXACIN 147059-72-1 ROFLEPONIDE 14**S9-70-1 TROVIRDINE 149488-17-5 RUFINANIDE 106308-U-S VEDAPROFEN 71109-09-6 RUZAOOLANE 11S762-17-9 VERSETANIDE 129009-83-2 SALNACEDIN 87573-01-1 VORICONAZOIE 137234-62-9 SAMIXOGREL 133276-80-9 VOTUNUHAR 148189-70-2 SANFETRINEN 156769-21-0 XANCMELINE 131986-45-3 SAPRtSARTAN 146623-69-0 ZAFIRLUKAST 107753-78-6 SEPRILOSE 133692-55-4 ZALEPLON 151319-34-5 SERATROOAST 112665-43-7 ZANAMIVIR 139110-80-8 SETIPAFANT 132418-35-0 ZANKIREN 138742-43-5 SPIROCLUMIDE 137795-35-8 ZIFROSILONE 132236-18-1 SPROOIAHtDE 138721-73-0 ZIPRASIDONE 146939-27-7 STACOFTLLINE 98833-92-2 ZQIASARTAH 145781-32-4 SULFADIAZINE tCDIUN 547-32-0 ZOIEDRONIC ACID 118072-93-8 SUICOEXIDE 57821-29-1 ZUCAPSAtCIN 25775-90-0 tUSALIMOD 149556-49-0 (2) . Table 2 of the Appendix Is modified by adding the following chemical or INN derivative names in alphabetical order:
ACETURATE ETHTLENEDIAMINE N-ACETTIGLTCINATE FARNESIL ACISTRATE FENOIZOATE ACOXIL FOSTEDATE ANSONATE HIBENZATE BENZATHINE HYBENZATE lEZOHIL HYCLATE RUCICLATE o-(4-NYOROXYBENZOYL)BENZOATE lUNAPSILATE ISOCAPROATE iUTEPRATE LAURIL •UTTL ESTER LAURILSULFATE CARBESILATE UUWYLSUIPNATE P-CHLOROWNZENESULFONATE MEGALUTE P-CHLOROSENZENEStaPHONATE METEMBONATE CICLOTATE 4-METNYLBICYCLO(2.2.2]OCT-2-ENE-1-CARBOXYUTE CIPIONATE NOFETIL CLOSILATE OCTIl CLOSYLATE OLAMINE CROaEFATE OXOCLURATE CRONACATE PENOETIDE CRCHESILATE PIVOXETIL CYCLOPENTANEPROPIONATE PROXETIL CYCIOTATE 1-PYRR0(.IDINEETHAN0L CYPIONATE SODIUM UURtL SULFATE DAPROPATE SODIUM LAURIL SULPHATE DEANIL SODIUM LAURTL SULFATE DECIL SODIUM LAURYL SULPHATE DIRUOINATE STEAGUTE DISUNATE TENOATE DIETHANOLAHINE TEPROSILATE DIGOLIL TETRADECYL HYDROGEN PHOSPHATE N,N-DIMETNYt-S-ALANINE TOFESILATE OIOIAMIHE TRICLOFENATE DCCOSIL TRIETNAHOLAMINE DOFOSFATE TRIFLUTATE EDAMINE TROIAMINE EDISTLATE TRCHETANOL EPOUNINE TROMETHAMINE ERMJHIHE TROXUNOATE ETABONATE XINOFOATE ETHANOIAMINE Ill STAT. 2876 PROCLAMATION 6982—APR. 1, 1997
Annex (continued) -4-
Sectlon B. (con.).
(3). Table 3 of the Appendix Is modified by deleting the products end CAS numbers In such table and Inserting the following products and CAS numbers In lieu thereof:
?rvti!\ Hum SASjUobsc 2-Ac*taiiildo-2-d*oxy-(-D-gtucopyr*nos* 7S12-I7-6 2-[(2-Ac*taiiildo-6-oiio-6,9-d
Annex (continued) -5-
Sectlon B. (con.).
(3). (con.):
Product Mwie CMIkmbT
S-(l*nzothUxol-2-yl) (Z)-Z-(2-Mlnothlazot-«-yl)-2-atthoiiy
Annex (continued) -6- Sectlon B. (con.).
(3). (con.):
rrWiWt »Wf CAS IMifctr
21-Chloro-9-B,11-t-tpoxy-17-hydrojiy-16-0-iMthylpr»flrw-1.4-ditn«-3,2O-dlon* 83881-08-7 (2-Ctitoro«thyl}dll«apropylMln« hydrochlorfde 4261-68-1 7-Chloro-1-«thyl-6-fluoro-1,4-dlhydro-4-ojioqulno(ln«-3-carboxy(lc acid 68077-26-9 3-(2-Chtaro«thy(>-2-iMthyl-4H-pyr
Annex (continued) -7-
Sectlon B. (con.)-
(3). (con.);
Product Mane wn 1-(2,6-0«chlorophenyl)«ndoUn-2-oo« 15362-40-0 3-(2.6-Dlch(oroph«nyl)-S-iiiethytltox»ol*-4-c«rbanyl chtorldt 4462-SS-9 1-(2,S-01chloraFh(nyl>plp*r«)nc hydrochloride 41202-77-1 tran«-(±}-4-(3,4-Olchloro|)h«nyt)-1.2,3,4-t*trahydro-1-niphthyt(acthyl)Maioniijiichlorfde 79617-99-S cU-2-(2,4-D1chtorophcfiyl)-2-(1N-1.2,4-trlazol-1-ylMthyl)-1,3-d)oi(ol*n-4-ylMthanot 67914-8S-6 o.3-DlchlorotolMn* 620-20-2 2',3'-Dldte)iyadM«w(n* 4097-22-7 DItnMtrol d<(ac*tatt) (INNM) 84-19-5 Diethyl •thoxyMthyterMMlonita 87-13-8 3,3-Dltthyl-S-(hydroxyMthyl)pyrldlnt-2.4(1M,3H)-dlon* 20096-03-1 DUthyUtllbMtrot dibutyrat* (INNM) 74664-03-2 DUthyUtllbMtrel dlproplonat* (INNM) 130-80-3 (Z)-3-a-(4-(2,4-Olfluoro-0-hydroxylBlnob*nzyl)plp«rldlno]cthyt}-6,7,8,9-t(tr*hydro-2- •Mthyt-4N-pyrldoC1,2-a]pyrlaldln-4-aM 132961-05-8 1-(4.4'-Difluorob«uhydryl)plptr*zln* 27469-60-9 6-a.9-Dlftuoro-11-S,17-0-dlhydroxy-16-o-Mthyl-3-oxoandro«t*-1,4-di«n*-17-t-carboxyllc acid 28416-82-2 2-<2,4-Dlfluoroph«iyl)-1,3-bU(1M-1,2,4-trlaiol-1-yl>propan-2-ol 123631-92-5 1-(2,4-Dlfluoroi3henyl)-6,7-d1fluoro-1,4-dlhydro-4-oxoquinatlnc-3-cirboxytlc acid 103995-01-3 (E>-(*)-2-(2,4-Olflooroph«nyl)-1-a-t4-(2,2,3,3-t»traflooropropoxy)»tyryl]-1H-1,2,4- trlaiol-1-yl>-3-(1H-1,2,4-trlaiol-1-yl)propan-2-ol 141113-28-2 (lt)-2-(2,4-Dlfluoroph«nyl)-3-(1H-1,2.4-trtazo(-1-yl)propanc-1,2-diol 141113-41-9 2,4'-OlfliJOro-2-(1N-1,2,4-trlaiol-1-yl)acttoph«non« hydrochloride 86386-75-6 1-(2,3-Dlhydro-1.4-tMnzodloxln-2-ylcarbanyl)piperazlne hydrochloride 70918-74-0 10.11-Dlhydro-5H-dibcnz(b,f]azepine 494-19-9 10,11-Dlhydro-5H-dlbcnzo(a,d]eyclohcpten-S-one 1210-35-1 3-(9,10-Olhydro-9,10-ethanoanthraccn-9-yl)acrylaldehyde 38849-09-1 N-{5-C(1,4-0ihydro-2-Mthyl-4-oxoquinazolln-6-ylMthyl)iMthylaiiiino]-2-thenoyl}- L-glutai»tc acid 112887-68-0 N-(S,6-Dlhydro-6-iiiathyl-2-aulfimoyl-4H-thlcnot2,3-b]thlopyr8n-4-yt)*ceta«iide 7,7-dioxlde 120298-38-6 (4s,6S>-S,6-Dihydro-6-aethyl-4H-thleno[2,3-blthiopyran-4-ot 7,7-dloxlde 147086-81-5 S,6-Dlhydro-4-oxo-4H-thlcnoC2,3-b]thllne-2-«ulfana«{de 105951-31-3 S,6-Dihydro-4-oxo-4H-thlenoC2,3-b]thllne-2-*ulfonaailde 7,7-dioxide 105951-35-7 «1l(,3R,5S>-3,5-Olhydroxy-2- ((E)-(3S)-3-hydroxyoct-1-cnyl]cyelopcntyl)acetic acid 56188-04-6 1,1-Ollioprapoxycyclohexanc 1132-95-2 Dllaopropyl photphorofluorldata 55-91-4 5,6-0lMthoxylndan-1-one 2107-69-9 1,1-DlMthoxy-2-(2-iRithoxyethoxy)ethane 94158-44-8 3,4-Diwthoxy-B-aethylphenethylMiilne 55174-61-3 (R)-6,7-OlMthoj(y-2-Mthyl-1-(3,4,S-triaethoxybcnzyl)-1,2.3,4-tetrahydroltoqulnaUne -•dIbcnzoyl-L-tartarIc acid (1:1) 104832-01-1 a,a-Dlmthoxy-2-nltrotolticna 20627-73-0 3,4-Dliiethoxyphenethylanlne 120-20-7 5,6-0lMthoxypyrlaldln-4-ylaailne 5018-45-1 6,7-DlMthoxyqulnazollne-2,4(1N,3H)-dlone 28888-U-O 4'-(2-(OiiBethylaaino>athoxy]-2-phcnylbutyrcphenone 68O47-07-4 (S>-4-(D-(2-Dlaethylaalnoethyl)-1N-lndol-5-yl]aethyt)oxazolldln-2-ofW 139264-17-8 (2S.3R)-4-Dlaethylamino-3-Mthyl-1,2-d Annex (continued) -8- Sectlon B. (con.). (3). (con.): Predict nm» CAS mmtmr 1-Ethyt-1,«-dlhydro-4-axb-1,3-d Annex (continued) -9- Sectlon B. (con.). (3). (con.): Prwtict Nit CAS lhiifc»r 2-Iodo-*-(1H-1,2,*-trUzol-1-yli»thyl)«nlMnt 160194-26-3 Itobutyl 3,4-tpoxybutyrat* 111006-10-1 1-lsoprapcnyl-1M-bcnzliiiidazol-2(3H)-on* S2099-72-6 3-l«opropoxy-5-iiiethoiiy-N-(1N-tttraiol-S-yl)tMnzotb]thlephtnf2-carbexMild* 10479S-66-6 3-I*apropoxy-S-Mthoxy-N-(1H-t*trtzol>5-yl)b«nzetb]th Annex (continued) -10- Sectlon B. (con.). (3). (con.): Prc«fact Nawe CAS Murfeer 4-Nltrotwnzyl 6-(2-phMwxyacttMildo)p«nleltlan*t« 1-ox(d* 29707-62-8 p-Nitrobcnzyt (2ll,SR,6S)-6-|(ll)-1-hydroxy*thyt]-3,7-d<(»o-1-(zablcyclo(3.2.0]htptan«- 2-carboxy(at« 75363-99-4 3-(4>Nltro|)h«nyl>-L-atanint 949-99-5 4-ll Annex (continued) -11- Sectlon B. (con.). (3). (con.): Product Mawe Vli ttfttr M'6-Trlfluoro«ettyl-L-ly«yl-L-prollnt 103J0O-B9-6 N'«-Trlfluoro»eetyl-L-ly»yl-L-prolln» p-tolucnMulfonitt 10SM1-23-* Proclamation 6983 of April 8,1997 National Former Prisoner of War Recognition Day, 1997 By the President of the United States of America A Proclamation Throughout the annals of American miHtary history, our men and women in uniform have placed themselves in great peril for the benefit of our Nation. Many of these courageous guardians of our freedoms have been held against their will as prisoners of war. The American people, including those now serving in our Armed Forces, continue to hold in the highest esteem these men and women who suffered the loss of their personal freedom and, in some instances, their lives. Although there is no threat of a major conflict in our immediate future, we face continuing military challenges, and our Armed Forces still de ploy "in harm's way" to maintain American interests and stability throughout the world. Whether attempting to keep the peace in Bosnia, evacuating American citizens from Albania, or patrolling the world's seas and skies, our service men and women risk capture by unfriendly foreign forces. American prisoners of war have always proudly struggled for their freedom and have demonstrated a profound dedication to their coun try. Although international law, as set forth in the Geneva Convention, confers a protected status on prisoners of war, many Americans faced difficult conditions, including torture, but they persevered, taking com fort in their love of God, family, and country. We can never know the extent of the brutality and hardships many of them encountered, but we can express our sincere admiration for their courage and bravery. As we observe National Former Prisoner of War Recognition Day, we honor and recognize all American service personnel who endured de tention or captivity in the service of their Nation. We take comfort in knowing that despite enduring daily physical and mental trials, many survived and returned to productive lives at home. But we remember and pay homage and respect to those who made the ultimate sacrifice while in enemy hands. Today, we enjoy the freedoms that generations of American men and women have fought to defend. Let us extend to Americans who were prisoners of war, and to their families, our pro found gratitude for their unselfish contribution to the preservation of our country. We will never forget.